PHG.F PHARMING GRP SP. ADRS
- Market cap
- EUR 807M
- P/E
- 40.7x
- P/B
- 3.07x
- ROE
- 8.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PHG.F undervalued?
Graham numberPHG.F trades 135.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
PHARMING GRP SP. ADRS fundamental analysis
No fundamental analysis for PHARMING GRP SP. ADRS yet.
PHARMING GRP SP. ADRS stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About PHARMING GRP SP. ADRS
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kd inhibitor for the treat…
Full company profilePHARMING GRP SP. ADRS financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
PHARMING GRP SP. ADRS annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 199M | 206M | 245M | 297M | 376M | 374M |
| Gross Profit | 178M | 188M | 220M | 262M | 331M | 325M |
| Operating Income | 19.0M | 9.86M | -22.3M | -3.67M | 20.9M | 29.6M |
| EBITDA | - | 33.5M | 9.88M | 16.3M | 34.8M | 41.2M |
| Net Income | 16.0M | 13.7M | -10.5M | -11.8M | 2.85M | 25.1M |
| EPS | 0.02 | 0.02 | -0.02 | -0.02 | 0.00 | 0.04 |
| Balance Sheet | ||||||
| Total Assets | 397M | 426M | 463M | 400M | 500M | 497M |
| Total Liabilities | 204M | 221M | 244M | 179M | 223M | 205M |
| Shareholders' Equity | 193M | 205M | 219M | 221M | 277M | 291M |
| Cash & Short-term Investments | 192M | 207M | 61.7M | 54.9M | 145M | 190M |
| Cash Flow | ||||||
| Operating Cash Flow | 37.8M | 22.5M | -17.3M | -1.80M | 54.7M | 32.9M |
| Capital Expenditure | 16.7M | 1.98M | 1.46M | 796K | 755K | 801K |
| Free Cash Flow | 21.1M | 20.5M | -18.8M | -2.59M | 54.0M | 32.1M |
| Ratios | ||||||
| ROE | 8.3% | 6.7% | -4.8% | -5.4% | 1.0% | 8.6% |
| ROA | 4.0% | 3.2% | -2.3% | -3.0% | 0.6% | 5.1% |
| Net Profit Margin | 8.0% | 6.7% | -4.3% | -4.0% | 0.8% | 6.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
PHARMING GRP SP. ADRS dividends
PHARMING GRP SP. ADRS has not paid dividends in the last 5 fiscal years.
Who owns PHARMING GRP SP. ADRS
- Insiders 0.00%
- Institutions 0.12%
- Public & others 99.88%
- Shares outstanding 70.8M
- Free float 67.3M
PHARMING GRP SP. ADRS company profile
- Company name
- PHARMING GRP SP. ADRS
- Ticker
- PHG.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 407
- Fiscal year end
- December
- Address
- Darwinweg 24, Leiden, Netherlands, 2333 CR
- Phone
- 31 71 524 7400
- Website
- pharming.com
About PHARMING GRP SP. ADRS
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kd inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3Kd inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
PHARMING GRP SP. ADRS management
10- Mr. Kenneth Lynard EMBA, M.Sc.CFO & Co-Chief Executive Officer · born 1968
- Ms. Leverne Marsh BPHARMCo-CEO & Chief Commercial Officer
- Ms. Mireille Sanders M.Sc.Chief Operations Officer · born 1968
- Mr. Michael K. LevitanVP of Investor Relations & Corporate Communications
- Mr. Ruud Van Outersterp L.L.M.Chief Legal & Compliance Officer and Company Secretary · born 1964
- Ms. Ines Bernal B.A.Chief People Officer
- Dr. Anurag Relan M.D., MPHChief Medical Officer · born 1972
- Dr. Alexander Breidenbach M.B.A., Ph.D.Chief Business Officer · born 1963
- Dr. Magnus HanssonMedical Director · born 1976
- Dr. Bruno M. L. GiannettiConsultant · born 1952